Compare ASH & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASH | RARE |
|---|---|---|
| Founded | 1924 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 2016 | 2013 |
| Metric | ASH | RARE |
|---|---|---|
| Price | $57.96 | $23.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 20 |
| Target Price | ★ $65.57 | $59.10 |
| AVG Volume (30 Days) | 1.0M | ★ 1.5M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.38% | N/A |
| EPS Growth | N/A | ★ 7.31 |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $1,824,000,000.00 | $673,000,000.00 |
| Revenue This Year | $2.58 | $13.12 |
| Revenue Next Year | $4.28 | $37.80 |
| P/E Ratio | $716.50 | ★ N/A |
| Revenue Growth | N/A | ★ 20.13 |
| 52 Week Low | $46.30 | $18.29 |
| 52 Week High | $65.65 | $40.17 |
| Indicator | ASH | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 58.14 | 47.24 |
| Support Level | $47.57 | $23.69 |
| Resistance Level | $60.79 | $25.70 |
| Average True Range (ATR) | 2.00 | 1.04 |
| MACD | 0.31 | -0.26 |
| Stochastic Oscillator | 86.40 | 29.67 |
Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.